deltatrials
Completed PHASE1 INTERVENTIONAL 1-arm NCT03406949

MGD009/MGA012 Combination in Relapsed/Refractory Cancer

A Phase 1, Open Label, Dose Escalation Study of MGD009, a Humanized B7-H3 x CD3 DART® Protein, in Combination With MGA012, an Anti-PD-1 Antibody, in Patients With Relapsed or Refractory B7-H3-Expressing Tumors

Sponsor: MacroGenics

Conditions Advanced Solid Tumors
Interventions obrindatamab retifanlimab
Updated 17 times since 2018 Last updated: May 18, 2022 Started: Feb 27, 2018 Primary completion: Apr 27, 2022 Completion: Apr 27, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03406949, this PHASE1 trial focuses on Advanced Solid Tumors and remains completed. Sponsored by MacroGenics, it has been updated 17 times since 2018, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Feb 2018 – ~Mar 2018 · 28 days · monthly snapshot~Mar 2018 – ~Jun 2018 · 3 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Sep 2018 · 2 months · monthly snapshot~Sep 2018 – ~Jan 2019 · 4 months · monthly snapshot~Jan 2019 – ~Mar 2019 · 59 days · monthly snapshot~Mar 2019 – ~Apr 2019 · 31 days · monthly snapshot~Apr 2019 – ~Sep 2019 · 5 months · monthly snapshot~Sep 2019 – ~Jun 2020 · 9 months · monthly snapshot~Jun 2020 – ~Sep 2020 · 3 months · monthly snapshot~Sep 2020 – ~Jan 2021 · 4 months · monthly snapshot~Jan 2021 – ~May 2021 · 4 months · monthly snapshot~May 2021 – ~Apr 2022 · 11 months · monthly snapshot~Apr 2022 – ~Jun 2022 · 2 months · monthly snapshot~Jun 2022 – ~Jul 2024 · 25 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 23 months · monthly snapshot

Change History

17 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  3. Jun 2022 — Jul 2024 [monthly]

    Completed PHASE1

    Status: Active Not Recruiting → Completed

  4. Apr 2022 — Jun 2022 [monthly]

    Active Not Recruiting PHASE1

  5. May 2021 — Apr 2022 [monthly]

    Active Not Recruiting PHASE1

▶ Show 12 earlier versions

  1. Jan 2021 — May 2021 [monthly]

    Active Not Recruiting PHASE1

  2. Sep 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE1

  3. Jun 2020 — Sep 2020 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  4. Sep 2019 — Jun 2020 [monthly]

    Recruiting PHASE1

  5. Apr 2019 — Sep 2019 [monthly]

    Recruiting PHASE1

    Status: Active Not Recruiting → Recruiting

  6. Mar 2019 — Apr 2019 [monthly]

    Active Not Recruiting PHASE1

  7. Jan 2019 — Mar 2019 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  8. Sep 2018 — Jan 2019 [monthly]

    Recruiting PHASE1

  9. Jul 2018 — Sep 2018 [monthly]

    Recruiting PHASE1

  10. Jun 2018 — Jul 2018 [monthly]

    Recruiting PHASE1

  11. Mar 2018 — Jun 2018 [monthly]

    Recruiting PHASE1

  12. Feb 2018 — Mar 2018 [monthly]

    Recruiting PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • MacroGenics
Data source: MacroGenics

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations